The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...
Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down ...
Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
2d
US approves oral drug for adults with rare type of lung cancer after early clinical trials globally
Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...
Glenmark Pharmaceuticals has partnered with China's Hansoh Pharma to commercialize Aumolertinib, a drug for non-small cell lung cancer, across multiple global markets. The agreement grants Glenmark ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one ...
The 52-year-old from Campbellsville was diagnosed with small cell lung cancer that had already spread to her brain. She was ...
Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.
GSK plc GSK announced that the FDA has granted Orphan Drug Designation to GSK’227, its investigational B7-H3-targeted ...
We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...
Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback